Fennec Pharmaceuticals Resubmits NDA for PEDMARK™

Fennec Pharmaceuticals Resubmits NDA for PEDMARK™

Fennec Pharmaceuticals has resubmitted their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARK™, a unique sodium thiosulfate formulation. PEDMARK is designed to prevent ototoxicity caused by cisplatin chemotherapy in patients under...